MERCK KGAA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 154.5 EUR | -0.64% |
|
+1.68% | +7.22% |
| May. 13 | Cinven to explore $3 billion sale of software maker Jaggaer, sources say | RE |
| May. 08 | MERCK KGAA : UBS reiterates its Buy rating | ZD |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 21.25B 22.94B | Sales 2025 * | 22.49B 24.27B | Capitalization | 67.17B 72.49B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.94B 3.18B | Net income 2025 * | 3.45B 3.72B | EV / Sales 2024 * | 3.47 x |
| Net Debt 2024 * | 6.6B 7.12B | Net Debt 2025 * | 4.8B 5.18B | EV / Sales 2025 * | 3.2 x |
| P/E ratio 2024 * |
22.6
x | P/E ratio 2025 * |
19.1
x | Employees | 62,908 |
| Yield 2024 * |
1.49% | Yield 2025 * |
1.57% | Free-Float | 29.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck KGaA
More press releases
| 1 day | -0.64% | ||
| 1 week | +1.68% | ||
| Current month | +3.73% | ||
| 1 month | +0.59% | ||
| 3 months | +2.08% | ||
| 6 months | +2.52% | ||
| Current year | +7.22% |
1 week
153.35
157.00
1 month
142.70157.00
Current year
140.50164.85
1 year
134.30172.40
3 years
134.30231.50
5 years
76.22231.50
10 years
60.83231.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 20-07-12 | |
Marcus Kuhnert
DFI | Director of Finance/CFO | 56 | 14-07-31 |
| Director of Finance/CFO | 53 | 19-04-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Christian Raabe
BRD | Director/Board Member | - | - |
| Chairman | 67 | 19-04-25 | |
Gabriele Eismann
BRD | Director/Board Member | 62 | 90-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.34% | 2 M€ | +13.56% | - | |
| 2.01% | 0 M€ | 0.00% | - | |
| 1.80% | 962 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 154.5 | -0.64% | 235,637 |
| 24-05-10 | 155.5 | -0.13% | 225,741 |
| 24-05-09 | 155.7 | +1.01% | 156,563 |
| 24-05-08 | 154.2 | +0.42% | 152,167 |
| 24-05-07 | 153.5 | +1.02% | 144,683 |
Delayed Quote Xetra, May 13, 2024 at 11:35 am EDT
More quotes
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows:
- solutions and products for scientific and biotechnological research (44.2%);
- pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.;
- performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc.
Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q1 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
154.5
EUR
Average target price
179.8
EUR
Spread / Average Target
+16.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.22% | 72.81B | |
| +12.72% | 9.13B | |
| -11.75% | 5.13B | |
| +59.61% | 4.99B | |
| +2.62% | 3.9B | |
| -17.54% | 2.48B | |
| +21.35% | 2.42B | |
| -27.82% | 2.32B | |
| +25.13% | 2.17B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- MRK Stock
